OncoQuest
Edmonton
About OncoQuest
The Company has assembled several bioactive technologies, including human and xenotypic monoclonal antibodies of the IgG and IgE class that can induce tumor specific immunity and enhance clinical outcome. Several of the lead components have clinical track records and extensive development dossiers that can be exploited to be integral to combinatorial immunooncology treatment strategies.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $50K – $100K
- Total funding: $69.0M
- Funding stage: Private Equity
- Last round: Private Equity (Mar 2020)
- Website: oncoquestinc.com
- Phone: 780-416-0324
Industries & Categories
Biopharma, Biotechnology, Health Care, Pharmaceutical, Wellness
Canonical: https://fsome.com/organization/oncoquest-49160 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.